Problems in the treatment of Parkinsonism by analeptics.
D000661:Amphetamine / Q000627:therapeutic use*; D000662:Amphetamines; D001058:Apomorphine / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D006801:Humans; D010300:Parkinson Disease / Q000628:therapy*; D020734:Parkinsonian Disorders; D010433:Pentylenetetrazole / Q000627:therapeutic use*
D000662:Amphetamines; D000697:Central Nervous System Stimulants; D000661:Amphetamine; D001058:Apomorphine; D010433:Pentylenetetrazole
AMPHETAMINE/therapeutic use; ANALEPTICS/therapeutic use; APOMORPHINE/therapeutic use; PARALYSIS AGITANS/therapy; PENTYLENETETRAZOLE/therapeutic use